Trial Profile
Randomized, Double-blind, Placebo Controlled, Parallel-group, Prospective Clinical Study to Analyse the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Chronic heart failure
- Focus Pharmacodynamics
- Acronyms ELSI
- 01 Jan 2023 Primary endpoint has been met, (Skin sodium content) as per Results published in the Clinical Research in Cardiology
- 01 Jan 2023 Results published in the Clinical Research in Cardiology
- 17 May 2021 Results assessing vascular function after treatment with empagliflozin presented at the 70th Annual Scientific Session of the American College of Cardiology